leadXpro AG announces its involvement in a multiparty research collaboration by delivering SARS-CoV-2 M-glycoprotein, a promising therapeutic target against Covid-19.
Latest developments, partnerships and scientific breakthroughs
One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
Lundbeck partners with leadXpro to discover drugs for membrane protein targets by high-resolution X-ray and cryo-Electron Microscopy
Astex Pharmaceuticals partners with leadXpro to facilitate structure-based drug discovery for membrane protein targets by cryo-Electron Microscopy
leadXpro and Sanofi collaborate for cryo-EM structure project
leadXpro determined the first protein structure at the Swiss Free Electron Laser (SwissFEL) facilities.
leadXpro AG and the University of Zurich (UZH) collaborate to generate sybodies as molecular discovery tools, therapeutic lead compounds and diagnostic reagents against disease-relevant membrane protein targets.